

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*



**Qyuns Therapeutics Co., Ltd.**  
**江蘇荃信生物醫藥股份有限公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*  
**(Stock Code: 2509)**

## **INSIDE INFORMATION**

### **LISTING APPROVAL GRANTED BY THE STOCK EXCHANGE FOR THE COMPANY'S H SHARE FULL CIRCULATION**

This announcement is made by Qyuns Therapeutics Co., Ltd. (the "**Company**") pursuant to Rule 13.09(2) of the Rules Governing the Listing of Securities on The Stock Exchange of Hong Kong Limited (the "**Stock Exchange**") (the "**Listing Rules**") and the Inside Information Provisions under Part XIVA of the Securities and Futures Ordinance (Cap. 571 of the Laws of Hong Kong).

References are made to (i) the announcement of the Company dated October 28, 2024 in relation to the acceptance by the China Securities Regulatory Commission (the "**CSRC**") of the Company's application to the CSRC for the proposed implementation of H share full circulation on behalf of certain shareholders of the Company (the "**Application**"); and (ii) the announcement of the Company dated January 21, 2025 in relation to the issuance of filing notice by the CSRC for the Application (collectively, the "**Announcements**"). Unless otherwise stated, terms used herein shall have the same meanings as those defined in the Announcements.

## **LISTING APPROVAL**

The Company has applied to the Listing Committee of the Stock Exchange for the approval (the "**Listing Approval**") of listing of and permission to deal in 17,322,400 H shares ("**Converted H Shares**"). The Company is pleased to announce that the Listing Approval was granted by the Stock Exchange on March 13, 2025. **The Listing Approval does not signify that the Converted H Shares have obtained all necessary approvals and passed all required procedures for listing. The Company will make further announcements in accordance with the Listing Rules as and when appropriate in relation to the progress of the Conversion and Listing.**

## **SHAREHOLDING STRUCTURE**

The Conversion and Listing will involve a total of three participating shareholders (the "**Participating Shareholders**") holding 17,322,400 Domestic Shares in issue, who will, after the Conversion and Listing, hold in aggregate approximately 7.80% of the total issued H shares of the Company.

The following is the percentage holding in the Company in relation to the Participating Shareholders upon completion of the Conversion and Listing:

| <b>Name of Participating Shareholders</b>  | <b>Number of<br/>Converted H<br/>Shares</b> | <b>Approximate<br/>percentage of<br/>the total number<br/>of issued H<br/>shares of the<br/>Company upon<br/>completion of<br/>the Conversion<br/>and Listing</b> |
|--|---|---|
| Mr. Qiu Jiwan (裘霽宛)  | 10,000,000                                  | 4.50%   |
| Taizhou Jianxin Venture Capital Co., Ltd.<br>(泰州健鑫創業投資有限公司)                                | 3,750,000                                   | 1.69%   |
| Jiaxing Jiquan Equity Investment Partnership (Limited Partnership)<br>(嘉興集荃股權投資合夥企業(有限合夥)) | 3,572,400                                   | 1.61%   |
| <b>Total</b>   | <b>17,322,400</b>                           | <b>7.80%</b>  |

*Note:* The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

The following is the share capital structure of the Company as at the date of this announcement and upon completion of the Conversion and Listing:

| <b>Class of shares</b>                   | <b>Immediately prior to<br/>the completion of the Conversion and<br/>Listing of the Domestic Shares</b> |                                       | <b>Upon completion of<br/>the Conversion and Listing of<br/>the Domestic Shares</b> |                                       |
|--|---|---------------------------------------|---|---------------------------------------|
|  | <i>Numbers of<br/>Shares</i>  | <i>Percentage<br/>(approximately)</i> | <i>Numbers of<br/>Shares</i>  | <i>Percentage<br/>(approximately)</i> |
| Unlisted Shares                          | 17,322,400  | 7.80%                                 | 0   | 0%                                    |
| H shares                                 | 204,749,200   | 92.20%                                | 222,071,600   | 100%                                  |
| <b>Total number of issued<br/>shares</b> | <b>222,071,600</b>  | <b>100%</b>                           | <b>222,071,600</b>  | <b>100%</b>                           |

*Note:* The percentages have been rounded up to the nearest two decimal places and any discrepancy between the totals and sums of amounts listed in the table is due to rounding.

**The Completion of the Conversion and Listing is also subject to other relevant procedures as required by the CSRC, the Stock Exchange and other relevant domestic and overseas regulatory authorities. The Company will make further announcements in accordance with the Listing Rules as and when appropriate in relation to the progress of the Conversion and Listing. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.**

By order of the Board  
**Qyuns Therapeutics Co., Ltd.**  
**Mr. Qiu Jiwan**

*Chairman of the Board and Executive Director*

Hong Kong, March 13, 2025

*As at the date of this announcement, the board of directors of the Company comprises Mr. Qiu Jiwan as chairman and executive director, Mr. Wu Yiliang and Mr. Lin Weidong as executive directors, Mr. Yu Xi and Mr. Wu Zhiqiang as non-executive directors, and Dr. Zou Zhongmei, Dr. Ling Jianqun and Mr. Fung Che Wai, Anthony as independent non-executive directors.*